Nektar Therapeutics (NKTR): Price and Financial Metrics

Nektar Therapeutics (NKTR): $3.54

0.08 (+2.31%)

POWR Rating

Component Grades













Add NKTR to Watchlist
Sign Up

Industry: Biotech



in industry


  • Quality is the dimension where NKTR ranks best; there it ranks ahead of 52.96% of US stocks.
  • The strongest trend for NKTR is in Stability, which has been heading down over the past 179 days.
  • NKTR's current lowest rank is in the Sentiment metric (where it is better than 2.29% of US stocks).

NKTR Stock Summary

  • Nektar Therapeutics's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 13.94% of US listed stocks.
  • Of note is the ratio of Nektar Therapeutics's sales and general administrative expense to its total operating expenses; merely 9.97% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for Nektar Therapeutics comes in at -33.36%, a number that bests only 5.13% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to NKTR, based on their financial statements, market capitalization, and price volatility, are MORF, CARA, MRTX, CCCC, and FATE.
  • NKTR's SEC filings can be seen here. And to visit Nektar Therapeutics's official web site, go to

NKTR Valuation Summary

  • In comparison to the median Healthcare stock, NKTR's price/sales ratio is 137.89% higher, now standing at 27.
  • NKTR's price/sales ratio has moved up 13.4 over the prior 243 months.
  • Over the past 243 months, NKTR's price/earnings ratio has gone down 2.7.

Below are key valuation metrics over time for NKTR.

Stock Date P/S P/B P/E EV/EBIT
NKTR 2021-08-31 27.0 3.1 -6.0 -6.0
NKTR 2021-08-30 26.4 3.1 -5.9 -5.9
NKTR 2021-08-27 26.1 3.0 -5.8 -5.8
NKTR 2021-08-26 24.8 2.9 -5.5 -5.5
NKTR 2021-08-25 25.1 2.9 -5.6 -5.6
NKTR 2021-08-24 24.5 2.9 -5.5 -5.5

NKTR Growth Metrics

    Its 2 year cash and equivalents growth rate is now at 552.31%.
  • Its 4 year revenue growth rate is now at -24.27%.
  • Its 5 year revenue growth rate is now at -24.27%.
NKTR's revenue has moved down $1,081,620,000 over the prior 34 months.

The table below shows NKTR's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 101.907 -412.66 -523.837
2021-09-30 100.36 -359.756 -495.395
2021-06-30 105.472 -311.295 -474.275
2021-03-31 125.989 -312.297 -428.756
2020-12-31 152.915 -313.287 -444.44
2020-09-30 163.315 -339.876 -440.675

NKTR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NKTR has a Quality Grade of C, ranking ahead of 63.19% of graded US stocks.
  • NKTR's asset turnover comes in at 0.072 -- ranking 285th of 682 Pharmaceutical Products stocks.
  • CALA, ACOR, and CGEN are the stocks whose asset turnover ratios are most correlated with NKTR.

The table below shows NKTR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.072 0.779 -0.370
2021-03-31 0.083 0.830 -0.314
2020-12-31 0.094 0.873 -0.301
2020-09-30 0.094 0.871 -0.268
2020-06-30 0.086 0.874 -0.230
2020-03-31 0.068 0.856 -0.223

NKTR Price Target

For more insight on analysts targets of NKTR, see our NKTR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.91 Average Broker Recommendation 1.68 (Moderate Buy)

NKTR Stock Price Chart Interactive Chart >

Price chart for NKTR

NKTR Price/Volume Stats

Current price $3.54 52-week high $19.37
Prev. close $3.46 52-week low $3.30
Day low $3.35 Volume 2,281,800
Day high $3.59 Avg. volume 3,390,461
50-day MA $4.76 Dividend yield N/A
200-day MA $11.28 Market Cap 659.41M

Nektar Therapeutics (NKTR) Company Bio

Nektar Therapeutics is a biopharmaceutical company, developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.

NKTR Latest News Stream

Event/Time News Detail
Loading, please wait...

NKTR Latest Social Stream

Loading social stream, please wait...

View Full NKTR Social Stream

Latest NKTR News From Around the Web

Below are the latest news stories about Nektar Therapeutics that investors may wish to consider to help them evaluate NKTR as an investment opportunity.

Nektar Therapeutics Q4 2021 Earnings Preview (NASDAQ:NKTR)

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.80 and the consensus…

Seeking Alpha | February 27, 2022

Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Toll-Like Receptor Agonist Pipeline Insights | Research Report 2022 by DelveInsight Toll-Like Receptor Agonist Pipeline constitutes 45+ key companies continuously working towards developing 45+ Toll-Like Receptor Agonist treatment therapies, analyzes DelveInsight DelveInsight''s Toll-Like Receptor Agonist Pipeline Insight 2022'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Toll-Like Receptor Agonist pipeline domain. Some of the essential takeaways from the Toll-Like Receptor Agonist Pipeline report: DelveInsight''s Toll-Like Receptor (TLR) Agonist...

Benzinga | February 21, 2022

Indices - Nektar Therapeutics Expected to Post Earnings of -$0.81 Per Share

Analysts forecast that Nektar Therapeutics will post earnings per share of for the current quarter, according to Zacks Investment Research. Five analysts have made estimates

Business Mag | February 20, 2022

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2021 on Monday, February 28, 2022, After Close of U.S.-Based Financial Markets

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2021 on Monday, February 28, 2022, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

Yahoo | February 17, 2022

Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for

Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Read More 'NKTR' Stories Here

NKTR Price Returns

1-mo -15.91%
3-mo -64.53%
6-mo -68.14%
1-year -80.41%
3-year -89.12%
5-year -82.97%
YTD -73.80%
2021 -20.53%
2020 -21.24%
2019 -34.33%
2018 -44.96%
2017 386.72%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8621 seconds.